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Systemic lupus erythematosus (SLE) is an autoimmune disease which behaves as a complex genetic trait. At
least 20 SLE risk susceptibility loci have been mapped using both candidate gene and genome-wide associ-
ation strategies. The gene encoding the pro-inﬂammatory cytokine, IL18, has been reported as a candidate
gene showing an association with SLE. This pleiotropic cytokine is expressed in a range of immune cells
and has been shown to induce interferon-g and tumour necrosis factor-a. Serum interleukin-18 has been
reported to be elevated in patients with SLE. Here we aimed to densely map single nucleotide polymorphisms
(SNPs) across IL18 to investigate the association across this locus. We genotyped 36 across IL18 by Illumina
bead express in 372 UK SLE trios. We also genotyped these SNPs in a further 508 non-trio UK cases and were
able to accurately impute a dense marker set across IL18 in WTCCC2 controls with a total of 258 SNPs. To
improve the study’s power, we also imputed a total of 158 SNPs across the IL18 locus using data from an
SLE genome-wide association study and performed association testing. In total, we analysed 1818 cases
and 10 770 controls in this study. Our large well-powered study (98% to detect odds ratio 5 1.5, with respect
to rs360719) showed that no individual SNP or haplotype was associated with SLE in any of the cohorts
studied. We conclude that we were unable to replicate the SLE association with rs360719 located upstream
of IL18. No evidence for association with any other common variant at IL18 with SLE was found.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a multisystem auto-
immune disease with complex symptoms affecting the skin,
blood cells, kidneys and joints (1). SLE is caused by multiple
environmental and genetic factors, with an incidence of 9:1
females to males, and a peak incidence age of 20–30 years
in females (2). A number of SLE genome-wide association
studies (GWASs) have been performed, conﬁrming at least
20 risk susceptibility loci (3–6). However, there are still a
number of published candidate gene studies which need
further investigation. One published candidate gene is IL18
(7), which reported to have a strong association between a
single nucleotide polymorphism (SNP) (rs360719) at the
IL18 locus, P ¼ 3.8 × 10
27, and SLE in three European popu-
lations (Spanish, Italian and Argentinean).
IL18 encodes a pro-inﬂammatory cytokine [interleukin-18
(IL-18)] located within a linkage region of SLE on chromo-
some 11 at 11q22.2–q22 (8–10), affecting both the innate
and acquired immunity (11). This cytokine is pleiotropic
which is inﬂuential to the development of T-helper 1 responses
(12). IL18 is expressed by a spectrum of immune cells such as
natural killer (NK) cells, dendritic cells and macrophages (13),
which induces interferon-g, tumour necrosis factor-a and gra-
nulocyte–macrophage colony-stimulating factor production.
Consequently, causing an increase in the cytotoxicity of NK
and T cells (14), a characteristic found in SLE patients.
Elevated IL-18 serum levels in SLE patients were pre-
viously reported (11), showing an increase as disease severity
intensiﬁes [361–1081 pg/ml in SLE patients compared with
100–126 pg/ml in controls (15)]. IL18 has functional rel-
evance to OX40L (16), a known SLE risk locus, where it
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dendritic cells (16). OX40L–OX40 interactions were reported
in maintaining T cell memory and survival of activated T cells
(17). Polymorphisms in this gene could result in the imbalance
of the immune response, which is a characteristic found in
SLE. Therefore, IL18 has many characteristics which
suggest it to be an SLE risk locus and so it is a good candidate
gene to investigate further.
Thus, genetic analysis of the IL18 locus in SLE is warranted
on the basis of it being a good functional candidate and prior
genetic data. Here we used a dense marker set across IL18
(Fig. 1) in a European SLE population, and we imputed and
analysed genetic data obtained from a GWAS in SLE.
RESULTS
Individual SNP association analysis in UK SLE trios
Three hundred and eighty UK trios were genotyped using a
customized Illumina BeadXpress chip, and the genotype data
were subjected to quality control (QC) checks, as described
in the Materials and Methods. From this, eight families were
removed due to Mendelian errors (families with .5%),
together with SNP 24 (rs4988359) which displayed deviation
from Hardy–Weinberg equilibrium (HWE) (P , 0.001).
Only SNPs with genotyping .90% were analysed. SNP 20
(rs360717) failed to genotype (genotyping ,90%) on the Illu-
mina platform and, therefore, was not included in further
analysis. All other SNPs were within HWE (P . 0.001) and
showed genotyping frequency of .90%.
The transmission disequilibrium test (TDT) analysis on the
372 trios was performed using PLINK-TDT. The results
(Table 1) of this analysis demonstrated that no individual
SNP association was found (P , 0.05). In addition, a
haplotype-TDT analysis using Haploview across the locus
showed no haplotypic associations.
Individual SNP association analysis in UK case–control
cohort (UK|CC)
Owing to the lack of association found in the UK SLE trios
cohort, an independent UK case–control cohort was analysed
to increase the power of the study. This case–control cohort
consisted of 508 UK non-trio cases, which were genotyped
on an Illumina bead express custom chip, and 2910 Wellcome
Trust Case Control Consortium controls (WTCCC2) [pre-
viously genotyped (18)]. However, since three SNPs geno-
typed in the UK cases were not present in the WTCCC2
controls, these SNPs were imputed in the WTCCC2 controls.
In a second phase of imputation, 508 cases and 2910 controls
were subjected to an imputation analysis to impute SNPs
between positions 111 464 762 and 111 653 000 bp (dbSNP
126) on chromosome 11. In total, 258 SNPs were imputed
in this region. Samples were imputed using the 1000
genomes CEU data as the phased reference (HapMap data
were not used as rs360719 is not a HapMap SNP) and trio
parents were used as the un-phased reference panel. Therefore,
the ﬁnal UK case–control association analysis cohort
(UK|CC) included both genotyped and imputed data from
258 SNPs. All imputed data were subjected to QC checks.
Two samples were removed for poor certainty (,90%).
SNP 9 (rs7938116) and SNP 24 (rs4988359) were excluded
for poor HWE (P , 0.001). All other SNPs showed good
HWE and genotyping greater than 90%. Five hundred and
eight cases and 2908 controls were then subjected to a
case–control analysis using SNPTEST.
First, we analysed the imputed UK|CC cohort for the 36 SNPs
initially genotyped in the UK SLE trio cohort. As seen in Table 1,
rs12797880, rs5744256, rs543810 and rs9919624 showed weak
associations (P ¼ 0.016, P ¼ 0.0027, P ¼ 0.015 and P ¼ 0.036,
respectively; however, after permutations to adjust for multiple
testing (10000 permutations) no individual SNP associations
were found (P , 0.05). To extend this analysis, we analysed the
remaining 222 imputed SNPs for individual SNP associations.
No other strong individual SNP associations were found (data
not presented) (P , 0.05) in the remaining 222 SNPs.
Imputation certainty
To ascertain whether the 1000 genomes CEU data were a good
source to use as the phased reference panel, we imputed the
UK|CC cohort using only the trio parents (n ¼ 744) as the
unphased reference and no phased reference was used. We
therefore imputed all 36 SNPs in both the cases and controls
(508 and 2908, respectively).
After imputation, the probabilistic genotypes were analysed
using SNPTEST; here an additive Frequentist model was
applied. The analysis showed weak individual SNP associ-
ations in SNPs rs12797880, rs4937113, rs5744256, rs543810
and rs9919624; however, after adjusting for multiple testing
no single signiﬁcant SNP association was found. Therefore,
when comparing this with the imputation performed in the
UK|CC cohort, using the 1000 genomes and unphased refer-
ence (Table 1), it can be seen that using only the unphased
reference does not alter individual SNP associations. Weak
associations are seen in the same SNPs when comparing
both imputations. Therefore, we can conclude that the 1000
genomes reference data were a good reference set to use for
this imputation, as using only the unphased reference panel
for the imputation gave results similar to when using the
1000 genomes and unphased reference simultaneously.
Haplotypic association analysis
The haplotypic architecture across the locus was constructed
using Haploview, with the solid spine algorithm and a D′
cut-off .0.8. None of the haplotypes showed association (P
, 0.05) in either the UK trios or UK|CC cohort. No risk hap-
lotype (haplotype more prevalent in the cases) or protective
haplotype (haplotype more prevalent in the controls) was
observed (Fig. 2).
Previous association with rs360719 analysis
As previously reported by Sanchez et al. (7), an association
was found for rs360719 (Pcombined¼ 3.8 × 10
27) (our SNP
17) in three southern European populations. Consequently,
we aimed to investigate this potential association further.
SNP rs360719 was not genotyped by Illumina (as described
in the Materials and Methods) because this SNP was
,100 bp away from other genotyped SNPs and therefore
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then imputed in the UK|CC cohort. The Taqman genotyping
for rs360719 in UK trios showed good clustering of genotypes,
indicating an accurate allele call rate. From these results, we
were unable to replicate the association previously found in
this SNP. The UK trio data showed that the A allele was over-
transmitted in this cohort and therefore not replicating the pre-
vious ﬁnding (7) where the G allele was found to be the risk
over-transmitted allele. However, in the UK|CC cohort, the
results show that the G allele was over-represented in the
cases; however, the P-value of 0.6 showed no signiﬁcant
association.
GWAS imputation and association analysis
As the results in the UK samples show that we were unable to
replicate the previous association (SNP 17 rs360719) (7), we
then used an SLE GWAS (19) data set and we imputed
missing SNPs at IL18 using the 1000 genomes project as refer-
ence data and the trios parents as the unphased reference (as
previously described). The European American GWAS geno-
type data comprised 60 SNPs across this region, where we
again imputed between positions 111 464 762 and 111 653
000 bp on chromosome 11. A total of 158 SNPs were
imputed (including rs360719). The imputation was performed
using IMPUTE V2 in 9170 individuals [1310 cases and 7860
controls (European American), using the 1000 genomes
(CEU) data as a phased reference panel].
Following imputation, the SLE GWAS was analysed using
SNPTEST where no individual SNP association was found.
SNP 17 (rs360719) demonstrated no evidence of an associ-
ation (P ¼ 0.784); however, the risk allele G, previously
shown to be associated, was found to be equal in both the
cases and controls and therefore we were unable to replicate
the ﬁnding by Sanchez et al. (7) in SLE. The marginal evi-
dence of association shown in the UKICC analysis, for
SNPs rs12797880, rs5744256, rs543810 and rs9919624, was
not replicated here. We also did not ﬁnd any haplotypic associ-
ation in this cohort.
Power calculation for rs360719
To ensure the two-study cohort had power to ascertain associ-
ation, a genetic power calculation was performed using the
sample size in the SLE GWAS European American case–
control cohort and UK|CC data. The result showed that we
have 99, 98 and 75% power to detect effect sizes of 1.81,
1.53 and 1.26, respectively, which is the range of odds ratios
(ORs) declared by Sanchez et al. (7), using an additive
model with one degree of freedom. This demonstrates that
the combined data set has sufﬁcient power to detect an associ-
ation in an SNP (rs360719) if present.
Bayes factors
Rather than formulate our results based on the null hypothesis
of no association (which we fail to reject for rs360719), we
can formally ask the question as to whether the data support
no association (null; OR ¼ 1) or an association as declared
by Sanchez et al. (7). This can be achieved by using the esti-
mated OR and standard error declared by Sanchez et al. (7)t o
formulate a prior distribution, and then calculating the Bayes
factor (BF) for the null model against the associated model.
We performed this analysis using SNPTEST.
For the UK case–control data, the BF in favour of the null
was 5.9 which is positive support (20), while for the European
data the BF was 50.5 which is strong. Combining the two BFs
gives a BF of 298 in favour of the null, which is very strong. If
we have equal prior belief in the models then this translates to
a probability for the null of 0.997 [probability of the null given
the data ¼ 0.997; probability that the OR is 1.53 (1.29,
1.81) ¼ 0.003]. The prior belief in models is subjective;
however, the BF is objective and coherent in that it averages
over a plausible range of ORs using the estimate and standard
error declared by Sanchez et al. (7).
Meta-analysis
A meta-analysis was performed on the joint UK SLE cohorts
using METAL (21) in the 36 genotyped SNPs. This analysis
Figure 1. (A) Gene diagram across chromosome 11 showing SNPs genotyped in this study. (B) IL18 gene showing the six exons along with the SNPs typed in
380 UK SLE trios. SNP 1 (rs7120010), SNP 2 (rs2564866), SNP 3 (rs2853127), SNP 4 (rs891360), SNP 5 (rs2518360), SNP 6 (rs2564871), SNP 7 (rs2518345),
SNP 8 (rs1367038), SNP 9 (rs7938116), SNP 10 (rs11214139), SNP 11 (rs2250417), SNP 12 (rs2518356), SNP 13 (rs11214127), SNP 14 (rs10891337), SNP 15
(rs12797880), SNP 16 (rs11214108), SNP 17 (rs360719), SNP 18 (rs1946519), SNP 19 (rs187238), SNP 20 (rs360717), SNP 21 (rs4937113), SNP 22
(rs360722), SNP 23 (rs360721), SNP 24 (rs4988359), SNP 25 (rs5744256), SNP 26 (rs549908), SNP 27 (rs5744280), SNP 28 (rs543810), SNP 29
(rs243908), SNP 30 (rs578784), SNP 31 (rs4937075), SNP 32 (rs10891323), SNP 33 (rs11214093), SNP 34 (rs360726), SNP 35 (rs10789859), SNP 36
(rs9919624).
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SNP
number
SNP Trios 372 families Case control, n ¼ 3416 (508 cases, 2908 controls) uPMETA
HWE Percentage
genotyping
MAF Alleles
(Maj:MA)
T:U Chi-square P-value HWE Percentage
genotyping
Associated
allele
Frequency
case, control
Chi-square P-value
1 rs7120010 0.025 99.4 0.072 G:A 59:44 2.18 0.120 0.198 99.8 A 0.089, 0.080 0.918 0.338 0.263
2 rs2564866 0.694 99.3 0.272 T:C 146:136 0.355 0.516 0.444 99.8 T 0.268, 0.259 0.361 0.548 0.330
3 rs2853127 0.768 99.2 0.302 C:T 150:148 0.013 1.000 0.412 99.4 T 0.303, 0.289 0.869 0.351 0.336
4 rs891360 0.909 98.8 0.283 T:C 148:139 0.282 0.558 0.431 99.9 T 0.283, 0.259 2.747 0.097 0.060
5 rs2518360 0.887 99.2 0.283 G:A 149:144 0.085 0.728 0.527 99.7 G 0.287, 0.266 1.86 0.173 0.092
6 rs2564871 0.684 99.1 0.270 G:A 142:138 0.057 0.767 0.634 99.9 G 0.266, 0.259 0.197 0.657 0.413
7 rs2518345 0.755 99.2 0.296 T:C 156:146 0.331 0.530 0.853 99.9 T 0.281, 0.271 0.410 0.522 0.329
8 rs1367038 0.644 99.1 0.305 C:A 157:147 0.329 0.569 0.850 99.8 C 0.294, 0.279 0.984 0.321 0.184
9 rs7938116 1.000 100 0.009 T:C 7:4 0.818 0.405 – – – – – – 0.405
10 rs11214139 0.422 99.1 0.112 A:G 74:72 0.027 0.935 0.039 100 G 0.112, 0.106 0.378 0.539 0.457
11 rs2250417 0.443 97.6 0.473 G:A 168:167 0.003 0.952 0.128 97.5 A 0.479, 0.453 2.24 0.134 0.177
12 rs2518356 0.468 98.1 0.341 A:G 152:151 0.003 0.823 0.717 99.9 G 0.341, 0.311 3.46 0.063 0.113
13 rs11214127 0.576 99.2 0.266 G:A 142:130 0.529 0.549 0.633 99.8 A 0.255, 0.243 0.717 0.397 0.235
14 rs10891337 0.696 99.4 0.267 C:T 145:132 0.610 0.513 0.513 99.4 T 0.259, 0.246 0.789 0.374 0.245
15 rs12797880 0.568 99.2 0.235 T:C 129:128 0.004 0.951 0.573 99.4 T 0.771, 0.734 5.81 0.016 0.021
16 rs11214108 0.334 98.8 0.115 G:A 80:69 0.812 0.522 0.344 99.9 A 0.110, 0.101 0.846 0.358 0.269
17 rs360719 0.651 92.0 0.298 A:G 92:72 2.43 0.118 0.930 100 G 0.280, 0.272 0.262 0.608 0.276
18 rs1946519 0.502 98.1 0.416 C:A 171:154 0.889 0.386 0.199 99.6 A 0.409, 0.386 1.99 0.158 0.058
19 rs187238 0.088 99.2 0.291 C:G 143:132 0.440 0.476 0.951 99.9 G 0.282, 0.273 4.07 0.523 0.336
20 rs360717 – – – – – – – 0.951 99.9 A 0.281, 0.273 0.306 0.580 0.465
21 rs4937113 0.181 98.5 0.427 T:A 164:162 0.012 0.828 0.859 99.7 A 0.425, 0.406 1.34 0.247 0.166
22 rs360722 0.800 98.5 0.096 C:T 68:59 0.638 0.486 0.047 99.9 T 0.105, 0.096 0.896 0.344 0.257
25 rs5744256 0.353 99.6 0.229 T:C 126:126 0.000 0.900 0.483 99.9 T 0.780, 0.736 8.98 0.0027 0.004
26 rs549908 0.443 98.0 0.332 T:G 149:145 0.054 0.818 0.899 99.7 G 0.321, 0.312 0.344 0.557 0.540
27 rs5744280 0.454 98.1 0.347 C:T 155:147 0.212 0.612 0.799 99.7 T 0.346, 0.329 1.05 0.305 0.370
28 rs543810 0.197 96.8 0.110 A:G 83:61 3.37 0.103 0.049 99.8 G 0.121, 0.096 5.97 0.015 0.009
29 rs243908 0.442 98.5 0.330 T:C 151:143 0.218 0.605 0.780 99.8 C 0.320, 0.312 0.258 0.612 0.529
30 rs578784 0.417 99.2 0.297 C:T 140:140 0.000 0.906 0.713 99.9 T 0.287, 0.284 0.048 0.827 0.824
31 rs4937075 0.061 98.8 0.304 C:G 143:140 0.032 0.814 0.500 99.8 G 0.296, 0.286 0.419 0.518 0.532
32 rs10891323 0.219 99.5 0.125 C:T 82:78 0.100 0.752 1.0 99.8 T 0.887, 0.883 0.131 0.717 0.526
33 rs11214093 0.315 97.6 0.430 T:C 168:157 0.372 0.786 0.763 99.8 T 0.424, 0.418 0.132 0.716 0.878
34 rs360726 0.352 99.2 0.228 C:T 136:115 1.76 0.351 0.598 99.8 T 0.225, 0.198 3.85 0.050 0.020
35 rs10789859 0.451 98.0 0.344 C:T 174:162 0.429 0.830 0.087 99.4 T 0.670, 0.652 1.24 0.265 0.307
36 rs9919624 0.026 99.9 0.013 G:A 11:9 0.200 0.513 0.487 100 G 0.015, 0.008 4.39 0.036 0.045
Table showing the allelic association comparison between the UK SLE trio cohort and the UK|CC cohort. SNP numbers correspond to those in Figure 1, all HWE and MAF are stated. uPMETA represents the
meta-analysis unpermuted P-value.
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9combines the P-values from both cohorts to ascertain associ-
ation between these SNPs and SLE. From the analysis,
four SNPs were found to have marginal association,
rs12797880 (SNP15) P ¼ 0.021, rs5744256 (SNP25) P ¼
0.004, rs360726 (SNP34) P ¼ 0.02 and rs9919624 (SNP36)
P ¼ 0.045. However, after permutation to adjust for multiple
testing (10000 permutations), these SNPs showed no evidence
of association.
Subphenotype analysis
We performed a subphenotype analysis on anti-Ro, anti-La,
age of onset (juvenile lupus versus adult lupus and mean age
interquartile range) and renal disease in 508 non-trio cases
using PLINK. No individual SNP association was found in
any of the subphenotype groups.
DISCUSSION
The work presented in this manuscript describes a detailed
ﬁne-mapping of variants across the IL18 locus, in a large
UK SLE data set followed by a meta-analysis and analysis
of a SLE GWAS cohort. The results of the association
studies in the UK SLE trios and UK|CC showed no individual
SNP or haplotypic association observed across IL18. This
suggests that common genetic polymorphisms at IL18 do not
exert a signiﬁcant genetic effect in the development of SLE.
In this study, we analysed three cohorts to investigate the poss-
ible association between IL18 and SLE; however, even in the
largest cohort (GWAS data), no individual SNP association
was found. A power calculation for the imputed case–
control SLE GWAS cohort showed 98% power [effect size
1.53 (7)] to detect a previously reported association. To
conﬁrm our results, we performed a meta-analysis between
the UK SLE trios cohort and the imputed UK|CC. This analy-
sis showed marginal associations in four SNPs; however, after
permutations these SNPs did not demonstrate signiﬁcant stat-
istical associations.
In this study, we failed to replicate the association found
by Sanchez et al. (7) in rs360719 (upstream of IL18) in our
initial UK cohorts. We therefore imputed European Ameri-
can SLE GWAS data using the 1000 genomes data set as a
phased reference panel, to try and replicate this ﬁnding.
After imputation of the SLE GWAS cohort, no association
was found with rs360719, therefore we were unable to repli-
cate the previous ﬁnding (7). SNPs in linkage disequilibrium
(LD) with SNP 17 (rs360719) were also analysed to dis-
cover whether another SNP in LD with rs360719 was
Figure 2. (A)U K |CC data showing SNPs which were genotyped and imputed. Haplotype constructed from 508 cases and 2608 controls. Tagger SNPs are indi-
cated by an asterisk. Numbers across the top of the haplotypes correspond to the SNP numbers in Figure 1. The haplotype number is in bold on the left of each
haplotype. Haplotype frequencies are shown after each block in bold. (B) LD plot from Haploview which shows the pattern of LD across the UK|CC population
with the brightest red showing regions of high pairwise D′.
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vidual SNP associations were found.
ApreviousassociationfoundatSNPrs360719(Sanchezetal.
(7)) was shown to be strongly associated in a Spanish cohort
(P-value of 7.8 × 10
27). As we were unable to replicate this
ﬁnd in our European cohort, we further explored whether
there are differences in the minor allele frequency (MAF) at
this SNP between southern and northern European populations.
Here we compared the MAF found by Sanchez et al. (7) control
data with our UK|CC control data and dbSNP. The MAF in
Sanchez et al. (7) control data was 25% compared with 27%
in our UK|CC data and 26% in dbSNP CEU control data. This
suggests that the MAF does not differ between the southern
and northern European populations and therefore cannot
account for the association found in the southern European
population. We also hypothesized that the previous association
foundwasduetolong-rangeLDwithrs360719andotherSNPs;
however, after long-rangeLD analysis of 500 kb up- and down-
stream of SNP rs360719, we can conclude that no other SNP in
LD with this SNP was found to be associated and therefore
cannot account for the previous association.
Our study covers a wider range across the IL18 locus, gen-
otyping 36 SNPs (Fig. 1A and B) and imputing 158 SNPs in
the SLE GWAS cohort and 258 SNPs in the UK|CC cohort.
We therefore had a dense analysis across IL18 to ascertain
association between these SNPs and SLE. Our cohort sizes
are also large, allowing us to have good power to detect the
previously reported association.
IL18 polymorphisms have previously been reported to be
associated in other autoimmune diseases such as rheumatoid
arthritis (RA) and type 1 diabetes (T1D). SNPs rs1946518 and
rs187238 were found to contribute to RA pathogenesis in
German patients (12) and rs1946518 was found to be present in
younger RA patients (22); this SNP may only be associated
with certain RA disease parameters such as the age of onset. In
our analysis, we are unable to report any associations between
these polymorphisms and SLE. SNPs rs1946518 and rs187238
have also been reported to be associated with T1D susceptibility
and CTLA-4 gene–gene interactions (23), however we did not
ﬁnd association in either of these SNPs in our cohorts for SLE.
Disruption and differences in transcription binding sites in T1D
caused by IL18 polymorphisms rs1946518 and rs187238 (24)
havebeenreported,howeverweagaindidnotﬁndanyassociation
with these SNPs in any of our cohorts with SLE patients. These
ﬁndings suggest that IL18 polymorphisms have a greater effect
in other autoimmune diseases compared with SLE.
In conclusion, we found no individual SNP or haplotypic
association across IL18 in the UK samples between the 36
SNPs genotyped or the 258 imputed SNPs and SLE. We
also failed to replicate the association for rs360719 previously
reported (7) after imputation analysis. Therefore, it is unlikely
that common variants in IL18 make a signiﬁcant contribution
to disease susceptibility in SLE.
MATERIALS AND METHODS
Study cohorts
UK cohort. The UK samples were a collection of UK lupus
patients and parental samples available in the laboratory. In
total, there were 380 trios (parents and their affected off-
spring). SLE patients were diagnosed through written ques-
tionnaires, telephone interviews and clinical notes, and
family members were contacted. Both patients and family
members gave written consent for the use of their DNA for
research within the laboratory. Ethical approval was granted
by the MREC (Multi-Centre Research Ethics Committee). A
total of 2910 Wellcome Trust case control consortium controls
(WTCCC2) were also used for the analysis of data.
SLE European American GWAS cohort. Genotype data on a
total of 1310 cases and 7860 controls (European population)
were obtained from Dr Robert Graham (Genentech) (25).
These controls were of mixed European populations compared
with only a UK population in the WTCCC2 controls. Samples
were subjected to QC tests as reported (19), together with
EIGENSTRAT analysis for population substructure clustering
using 10 principal components. This EIGENSTRAT analysis
excluded 141 samples as described (19).
Sample collection
Preparation of DNA. Whole blood was collected and lympho-
cytes were separated from whole blood by centrifugation;
genomic DNA was isolated using the phenol-chloroform
method.
SNP selection. Using HapMap B36 assembly dbSNP 126, 21
haplotype-tagging SNPs across IL18 were selected (tagging
parameters set at R
2 cut-off 0.8, MAF cut-off 0.2) together
with 14 functional SNPs from previous association studies
(Fig. 1). SNPs rs360718, rs360719, rs1946518, rs12721559
and rs360721 were removed from selection, as these SNPs
were less than 100 bp apart and therefore could not be
pooled together for the customized Illumina chip.
Genotyping
Samples were genotyped on an Illumina bead express custom
chip at the Oklahoma Medical Research Foundation (OMRF).
SNP rs360719 was genotyped using a Taqman assay from
Applied Biosystems according to the manufacturer’s instruc-
tions. The genotype data for the variant were quality con-
trolled using the SDS 2.3 software (Applied Biosystems).
Statistical analysis
All genotype and phenotype data were managed and analysis
ﬁles produced within BC|SNPmax (Biocomputing platforms,
Finland).
All data underwent general quality checks which consisted
of Mendelian error analysis (families with .5%) for the
trios along with HWE analysis for both trios and case–
control data (cut-off 0.001).
Haplotype structures were generated for both the UK trios
and the UK|CC cohorts using the solid spine algorithm in
Haploview based on the LD between SNPs (http://www.
broadinstitute.org/mpg/haploview) with conﬁdence intervals
of 0.98 and 0.70 for LD. Markers with minor allele frequen-
cies of ,5% were excluded from the haplotype blocks.
Human Molecular Genetics, 2011, Vol. 20, No. 5 1031Allelic associations for the UK SLE trios were tested using
the TDT in PLINK, which compares expected and observed
transmission of alleles from parents (heterozygous) to the
affected offspring. Haplotypic architecture of the genotyped
SNPs was constructed using Haploview. A case–control
analysis in Haploview was then performed in UK|CC cohort
and SLE European American GWAS.
Bayes factors
We calculated the BFs by running a logistic model in
SNPTEST using the Bayesian option with a Gaussian prior
distribution on the log ORs with a mean of 0.425 and standard
deviation of 0.086, which corresponds to an expectation of
1.53 for the OR with upper and lower 95% conﬁdence
bounds of 1.29 and 1.81, respectively. These ﬁgures are
taken directly from Sanchez et al. (7).
Imputation
The 508 UK cases and 2910 UK controls were subjected to an
imputation analysis to impute SNPs between positions 111 464
762 and 111 653 000 bp (dbSNP 126). A total of 258 SNPs
were imputed in this region using IMPUTE V2. Samples
were imputed using the 1000 genomes CEU data as the
phased reference. Imputed data were uploaded as probabilistic
genotypes and individual SNP associations were analysed
using SNPTEST, while haplotypic associations were analysed
as previously described.
SLE European American GWAS genotype data were
obtained and imputed using IMPUTE V2 (26) within
BC|SNPmax. Genotype data were imputed using 1000
genomes (Caucasian) data as a phased reference panel and
IL18 Caucasian trio data as the unphased reference. Imputa-
tion regions were set to 111 464 762 to 111 653 000 bp on
chromosome 11. Imputed data were uploaded as probabilistic
genotypes and analysed for HWE and haplotypic associations
as described previously.
Meta-analysis
A meta-analysis using METAL (21) in the UK SLE trios and
the imputed UK|CC cohort in the 36 genotyped SNPs was
performed. This analysis allowed the combination of
P-values in both cohorts to ascertain association between
these SNPs and SLE.
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